Clinical Trial

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 2, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
Open-label, two-arm, prospective multicenter phase II clinical trial to determine the efficacy and safety of combined pembrolizumab and lenvatinib compared to pembrolizumab alone as maintenance therapy after definitive radiochemotherapy of locally advanced head and neck squamous cell carcinoma (HNSCC).
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-06-20; most recent amendment 2025-11-24.
Status change: Recruiting → Active, Not Recruiting 2025-11-24
Status change: Not Yet Recruiting → Recruiting 2023-06-05
Trial Details
NCT Number NCT05433116
Lead Sponsor Universität des Saarlandes
Conditions Head and Neck Squamous Cell Carcinoma
Enrollment 50 participants
Start Date 2023-05-25
Primary Completion 2026-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-02